Bari

• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended recruitment
  2024-517143-31-00 4 2025-07-18 Autosomal Dominant Polycystic Kidney Disease
• AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI … Ended recruitment
  2023-505601-16-00 5 2025-04-22 Chronic Migraine
• Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended recruitment
  2024-512180-31-00 4 2025-03-14 Oligometastatic renal cell carcinoma
• Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger … Ended recruitment
  2024-516316-13-00 4 2025-01-21 Merkel cell carcinoma without metastases in other organs and surgicall
• PH 3b, CAB + RPV in people with suboptimal response to oral ART (CROWN) Ended recruitment
  2024-515070-28-00 5 2024-12-23 HIV Infections
• Potential protective role of SGLT-2 inhibitors for chemotherapy-induced cardiotoxicity (PROTECT trial) Ended recruitment
  2024-518611-18-00 4 2024-12-03 Chemotherapy-induced cardiotoxicity in breast cancer
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell … Ended recruitment
  2024-513539-25-00 4 2024-11-22 Type 2 Diabetes Mellitus
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended recruitment
  2023-506049-52-00 4 2024-10-28 Follicular lymphoma
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu … Ended recruitment
  2023-509762-38-00 5 2024-08-01 Respiratory Syncytial Virus Infections
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended recruitment
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla
• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan … Ended recruitment
  2023-503666-23-00 5 2024-06-07 Neovascular age-related macular degeneration
• Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended recruitment
  2023-503755-10-00 5 2024-05-17 Splenic marginal zone lymphoma
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either … Ended recruitment
  2023-503357-35-00 4 2024-03-20 Non-small Cell Lung Cancer (NSCLC)
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer

Showing 193–216 of 368 trials